June 2015
Volume 56, Issue 7
ARVO Annual Meeting Abstract  |   June 2015
Combined antiVEGF and Photodynamic Therapy for Hemangioblastoma of the Retina and the Optic Nerve
Author Affiliations & Notes
  • Irene Barbazetto
    Vitreous Retina Macula Consultants of New York, New York, NY
  • Footnotes
    Commercial Relationships Irene Barbazetto, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3448. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Irene Barbazetto; Combined antiVEGF and Photodynamic Therapy for Hemangioblastoma of the Retina and the Optic Nerve. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3448.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To evaluate the response of retinal and optic nerve hemangioblastoma to a combination treatment with photodynamic therapy (PDT) using Verteporfin (Visudyne,™ Valeant, Quebec, Canada) and intravitreal injections of anti-Vascular endothelial growth factor (VEGF) medications.


Retrospective case series of 4 patients with hemangioblastoma of the choroid or optic nerve. Changes in visual acuity (VA), optical coherence tomography (OCT) and fluoresceine (FA) and indocyanine green (ICG) angiography before and after treatment were evaluated.


Four eyes of 4 patients (4 male; mean age 48.7 years) were included. A total number of 7 hemangioblastomas were treated. Three patients were diagnosed with von Hippel-Lindau Disease. All patients received an intravitreal antiVEGF injection 1 - 2 weeks prior to PDT. Additional injections after PDT were given in case of persistent or recurrent edema. Persistent leakage on angiography was the bases for repeated PDT. Patients received an average of 2.5 PDT treatments (1-4). The men follow-up time was 18.3 months (5-24). Some degree of VA improvement was noted in all patients. On average patients gained 2.5 lines (1-5). Patients with lesions outside the macular were more likely to benefit with regard to functional gain. Improvement on OCT imaging, with reduction of retinal edema, subretinal fluid and/or lesion size was seen in all patients. Angiography confirmed a partial or complete closure after treatment in all patients. However recurrent leakage was seen in 4 of 5 patients.<br />


Treatment response varies depending on size and location of the hemangioblastoma. While anatomical and functional improvements are possible, complete and lasting angiographic closure is only rarely achieved.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.